Simulations Plus Partners with Large Pharmaceutical Company to Enhance the Mechanistic Oral Absorption (ACAT) Model in GastroPlus

November 14, 2019 Off By BusinessWire

Funded collaborative research effort adds new functionality to the top-rated simulation engine

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to modify the mechanistic oral absorption (ACAT™) model in GastroPlus® to support gastrointestinal disease research.

“What an exciting opportunity we have to participate in a collaboration which will enhance and advance understanding of local drug disposition in the gut tissue to assist with the development of new therapies for gastrointestinal diseases,” said Viera Lukacova, director of Simulation Sciences for Simulations Plus. “Working closely with our partner’s cross-functional team of DMPK, biopharmaceutics, and clinical pharmacology scientists, we intend to incorporate ground-breaking scientific approaches and validate the new methods using one-of-a-kind data collected by our partner.”

John DiBella, Lancaster division president for Simulations Plus, added: “Pharmaceutical companies have independently confirmed the GastroPlus physiologically based biopharmaceutics (PBBM) / physiologically based pharmacokinetic (PBPK) platform as the most accurate commercial tool available for predicting drug absorption following oral administration in animals and humans. This collaboration will look to build upon our 20-year foundation to improve the accuracy of drug concentrations in gut tissue within a supported, validated software program. Similar to other collaborations that funded the development of new functionality, Simulations Plus maintains the right to license this to all clients, and we aim to have the first version available in 2020. We welcome and invite future collaborations to drive advances to modeling and simulation sciences.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery/development software and a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. Our software is used to conduct drug research by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading provider for physiologically based pharmacokinetic modeling and simulation. Visit us online

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Follow us on Twitter | LinkedIn | YouTube


Simulations Plus Investor Relations
Ms. Renee Bouche


[email protected]

Hayden IR
Mr. Cameron Donahue


[email protected]